Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients

Table 1 Individual factors of patients with diverse responses at 52 wk after interferon-α therapy n (%)

Characteristic	Total (n = 147)	RS (n = 47)	NRS (n = 100)
Sex
Male	106 (72.1)	33 (70.2)	73 (73.0)
Female	41 (27.9)	14 (29.8)	27 (27.0)
Age (yr)	25.02 ± 056	26.40 ± 1.19	24.37 ± 0.59
ALT (U/L)	214.25 ± 17.38	226.23 ± 19.19	208.62 ± 23.94
HBV DNA
(log10 copies/mL)	7.16 ± 0.07	6.93 ± 0.14	7.27 ± 0.09
HBsAg
(log10 IU/mL)	4.11 ± 0.07	3.93 ± 0.14	4.20 ± 0.07
HBeAg
(log10 S/CO)	2.55 ± 0.07	2.30 ± 0.13a	2.67 ± 0.07a
Anti-HBc (S/CO)	11.13 ± 0.15	11.54 ± 0.27	10.94 ± 0.17
Genotype
B	85 (57.8)	26 (55.3)	59 (59.0)
C	55 (37.4)	21 (44.7)	34 (34.0)
Other	7 (4.8)	0 (0.0)	7 (7.0)

Data are presented as frequency counts (percentage of total) or mean ± SD.

^aP < 0.05, NRS vs RS. RS: HBeAg seroconversion; NRS: No HBeAg seroconversion; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen.